Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain

University of Baghdad

Status and phase: Enrolling; Phase 4

Conditions: Bruxism; Orofacial Pain

Treatments: Drug: Chlorzoxazone; Drug: Orphenadrine Citrate

Study type: Interventional

Funder types: Other

Identifiers

NCT07109882

1035425

Details and patient eligibility

About

To evaluate the clinical effectiveness of chlorzoxazone in comparison to orphenadrine Citrate in relieving the orofacial pain in bruxers. Subjects and Methods: 60 patients above 15-years old complaining of orofacial and temporomandibular disorder/pain, with no history of chronic systemic illness, will be recruited. Patients will randomly be allocated into two groups (n=30): the first group will receive Relaxon (chlorzoxazone) twice daily for two weeks, while the second group will receive Norgesic (orphenadrine Citrate) twice daily for two weeks as well. Pain severity will be assessed by Visual Analogue Scale (VAS) at day 0, 7, and day 14. In addition, a temporomandibular joint (TMJ) evaluation form will be utilized to assess the TMJ parameters before and after initiation of the treatment protocol, i.e at 0 and 14 days. Non parametric statistical analysis will be conducted to explain the results using SPSS V29.

Enrollment: 60 estimated patients

Sex: All

Ages: 15+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients aged above 15 years-old complaining of orofacial and temporomandibular disorder/pain.
• Patients with no history of chronic systemic illness.

Exclusion criteria

• Patients with orofacial injuries.
• Patients with head injuries.
• Patients Taking analgesics for the last 14 days.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups

Chlorzoxazone Group

Active Comparator group

Description:

Using Chlorzoxazone

Treatment:

Drug: Chlorzoxazone

Orphenadrine Citrate group

Active Comparator group

Treatment:

Drug: Orphenadrine Citrate